Welcome to the e-CCO Library!

DOP58: IdeaL: a multi-centre prospective infliximab dose to level pharmacokinetic study during induction in paediatric Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

G. H. Huynh*1, M. W. Carroll1, A. M. Griffiths2, W. El-Matary3, A. Petrova4, C. Prosser5, C. Kluthe6, J. C. deBruyn7, D. Tomalty2, D. R. Mould8, E. Wine4, H. Q. Huynh4

Created: Friday, 22 February 2019, 9:41 AM
DOP58: Non-white race is associated with decreased efficacy of tumor necrosis factor antagonist therapy in Ulcerative Colitis: A post-hoc analysis of individual level data from golimumab clinical trials
Year: 2021
Source: ECCO'21 Virtual
Authors: Greywoode, R.(1);Petralia, F.(2);Ullman, T.(1);Colombel, J.F.(3);Ungaro, R.(3)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP58: predictors of complicated disease course in CD in an administrative database: a nationwide study from the epi-IIRN
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Gili Focht
Created: Friday, 14 July 2023, 2:22 PM
DOP58: predictors of complicated disease course in CD in an administrative database: a nationwide study from the epi-IIRN
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Lujan, R.(1);Atia, O.(1);Gili, F.(1)*;Greenfeld, S.(2);Kariv, R.(2);Loewenberg Weisband, Y.(3);Lederman, N.(4);Matz, E.(5);Dotan, I.(6);Turner, D.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP58: Tofacitinib for Ulcerative Colitis: Results of the ICC Registry, a nationwide prospective observational cohort study
Year: 2020
Source: ECCO'20 Vienna
Authors: Jasmijn Sleutjes
Created: Tuesday, 23 June 2020, 5:40 PM
DOP58: Tofacitinib for Ulcerative Colitis: Results of the ICC Registry, a nationwide prospective observational cohort study
Year: 2020
Source: ECCO'20 Vienna
Authors: Jasmijn Sleutjes
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP59 Maintenance of remission with tofacitinib in patients with ulcerative colitis: Updated results of a subpopulation analysis from an open-label, long-term extension study, OCTAVE Open
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J.F. Colombel1, M.T. Osterman2, P. Ibanez3, A.J. Thorpe4, H. Zhang4, N. Lawendy4, C. Su4, W. Reinisch5

Created: Thursday, 30 January 2020, 10:12 AM
DOP59: Development of a novel Ulcerative Colitis (UC) endoscopic activity prediction model using machine learning (ML)
Year: 2022
Source: ECCO'22
Authors: Colombel , J.F.(1);Rubin , D.(2);Schott , J.P.(3);Gottlieb , K.(4);Erisson , L.(5);Prucka , B.(6);Phillips , S.(5);Kwon , J.(7);Ng , J.(8);McGill , J.(4);
Created: Friday, 11 February 2022, 3:52 PM
DOP59: Evaluation of the efficacy of tofacitinib as maintenance therapy in patients with Ulcerative Colitis stratified by OCTAVE Sustain baseline endoscopic subscore
Year: 2021
Source: ECCO'21 Virtual
Authors: Lee, S.D.(1);Allegretti, J.R.(2);Steinwurz, F.(3);Connelly, S.B.(4);Lawendy, N.(4);Paulissen, J.(5);Gecse, K.B.(6)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP59: Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Raimundo Fernandes*1, S. Bernardo1, C. Simões1, L. Correia1, P. Moura Santos1, A. Rita Gonçalves1, A. Valente1, C. Baldaia1, R. Tato Marinho1

Created: Friday, 22 February 2019, 9:41 AM
DOP59: Proactive Infliximab Drug Monitoring Is Superior To Conventional Management In Inflammatory Bowel Disease
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Samuel Raimundo Fernandes
Created: Tuesday, 28 May 2019, 3:32 PM
Anti TNF drug levels, Mucosal healing, Therapeutic drug monitoring, Infliximab
Files: 1
DOP59: What is the relationship between fatigue, pain and urgency in people with inflammatory bowel disease? Results of the IBD-BOOST survey in 8486 participants
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Hart, A.(1);Miller, L.(2);Hamborg, T.(2);Stagg, I.(1);McGuinness, S.(3);Wileman, V.(4);Tzorovili, E.(2);Mihaylova, B.(2);Roukas, C.(2);Aziz, Q.(5);Czuber-Dochan, W.(3);Dibley, L.(6);Moss-Morris, R.(7);Pollok, R.(8);Saxena, S.(9);Winsor, G.(10);Norton, C.(3)*;
Created: Friday, 14 July 2023, 10:43 AM
DOP60 Vedolizumab treatment persistence and safety in an extended access program (XAP)
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Danese1, K. Subramanian2, J. Van Zyl3, S. Adsul4, D. Lindner5, J. Roth6, S. Vermeire7

Created: Thursday, 30 January 2020, 10:12 AM
DOP60: Environmental risk factors for Inflammatory bowel disease: A large prospective case-control study in India
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Rupa Banerjee
Created: Friday, 14 July 2023, 2:22 PM
DOP60: Environmental risk factors for Inflammatory bowel disease: A large prospective case-control study in India
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Banerjee, R.(1)*;Pal, P.(1);Prakash, N.(1);Mudigonda, S.(1);Joseph, S.(1);Patel, R.(1);Khalil, M.(1);Komawar, A.(1);Korikana, S.(1);Mekala, D.(1);Akki, Y.(1);Gaddam, A.(1);Valluri, S.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP60: Prevalence of undiagnosed inflammatory Bowel Disease in patients with spondyloarthritis: EISER Study
Year: 2024
Source: ECCO'24 Stockholm
Authors: Gutiérrez Casbas, Ana
Created: Tuesday, 30 April 2024, 5:03 PM